Xilio Therapeutics logo
Xilio Therapeutics
XLO | NASDAQ
Chart Builder DCF Calculator
$7.70
-$0.37 (-4.64%)
At close: Nov 16, 2026, 4:00 PM ET
$7.70
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Xilio Therapeutics Company Profile

Company profile explained

Company Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

Key Executives

Name Position
Rene Russo BCPS President, Chief Executive Officer & Director
Benjamin S. Harshbarger Chief Legal Officer
Christopher Frankenfield Chief Financial Officer & Chief Operating Officer
Nathan McBride Chief Information Officer
Kevin Brennan Senior Vice President of Finance & Accounting
Ruth du Moulin Senior Vice President of Medical Affairs
Scott Coleman Chief Development Officer
Uli Bialucha Chief Scientific Officer
Yariv Houvras Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 3 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 S-8 Filing
Aug 12, 2026 10-Q Quarterly Report
Aug 12, 2026 8-K Current Report
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
View All SEC Filings ➞
Xilio Therapeutics
Xilio Therapeutics logo
Country United States
IPO Date Oct 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 76
CEO Rene Russo

Contact Details

828 Winter Street Waltham, Massachusetts 02451 United States

Stock Details

Ticker Symbol XLO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001840233
CUSIP Number 98422T209
ISIN Number US98422T2096
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.